Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1647 1658 1683
This examiner grants 48% of resolved cases
Audrey L. Buttice has 142 resolved cases in Tech Center 1600. The allowance rate is 47.9 percent. The median days to allowance is 1266. These 142 resolved cases are the basis for the metrics in Art Unit 1644. The 1266-day median provides a timeline for the cases resolved by this examiner and helps in estimating the duration of prosecution.
The interview lift is 25.9 percent. This metric indicates the change in allowance probability when an interview is conducted. Given the 47.9 percent allowance rate, the 25.9 percent lift is a factor for practitioners to consider. In Tech Center 1600, the lift is a data point for strategy. The 142 resolved cases reflect the examiner's experience with various applications. The 1266-day median pendency is a reference for future filings and for planning examiner engagement.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18417787 | BRAIN TARGETING COMPOSITIONS AND METHODS OF USE THEREOF | Non-Final OA | Genentech, Inc. |
| 17774821 | COMBINATION OF A T CELL THERAPY AND (S)-3-[4-(4-MORPHOLIN-4-YLMETHYL-BENZYLOXY)-L-OXO-L,3-DIHYDRO-ISOINDOL-2-YL]-PIPERIDINE-2,6-DIONE | Final Rejection | Juno Therapeutics, Inc. |
| 18249057 | USE OF REELIN FOR TREATING CARDIAC DISEASES | Final Rejection | Northwestern University |
| 16951638 | METHOD OF USING CHECKPOINT KINASE INHIBITOR THERAPY TO MODULATE ANTI-TUMORAL RESPONSE AGAINST CANCER AND SENSITIZE GLIOMAS TO IMMUNOTHERAPY | Final Rejection | NORTHWESTERN UNIVERSITY |
| 18040586 | METHODS AND COMPOSITIONS FOR PANCREATIC CANCER EVALUATION AND TREATMENT | Final Rejection | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM |
| 18006652 | ENGINEERED T CELLS AND TUMOR-INFILTRATING LYMPHOCYTES TO INCREASE TUMOR KILLING | Non-Final OA | Board of Regents, The University of Texas System |
| 17242647 | Method For The Degradation Of Endogenous Protein | Non-Final OA | University of South Carolina |
| 18120191 | PROGRAMMED CELLS FOR TARGETED ARTICULAR CARTILAGE AND BONE REGENERATION | Non-Final OA | University of Tennessee Research Foundation |
| 18245281 | CYTOTOXIC AND COSTIMULATORY CHIMERIC ANTIGEN RECEPTORS | Final Rejection | Baylor College of Medicine |
| 18266848 | CONDITIONALLY BISPECIFIC BINDING PROTEINS | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18021845 | COMBINATION THERAPY COMPRISING HER-2-DC1 VACCINE AND A PROBIOTIC | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17434692 | INDUCTION OF HIGHLY EFFICACIOUS ANTI-TUMOR AND IMMUNE MODULATING ACTIVITY: CELL-FREE OFF THE SHELF THERAPEUTIC MODALITY | Final Rejection | Wayne State University |
| 18561682 | HYPOIMMUNOGENIC RHD NEGATIVE PRIMARY T CELLS | Non-Final OA | Sana Biotechnology, Inc. |
| 18573798 | FORMULATIONS OF ANTI-PD1 ANTIBODIES | Non-Final OA | Formycon AG |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy